Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection (CAPOGA): A Large Multicenter Phase III Randomized Controlled Trial
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 768
- 试验地点
- 1
- 主要终点
- Disease-free/Relapse-free survival
研究概览
简要总结
Gastric cancer (GC) is one of the most common and lethal malignancies in Asia. For early (stage T1) GC, it has been found by analyzing surgical specimens that ~5% of cancers have lymph node metastasis. For patients with stage T2-3N0M0 GCs, there is a considerable probability of micro-metastasis. While the US National Comprehensive Cancer Network (NCCN), the Japanese Gastric Cancer Association (JGCA), and the European Society for Medical Oncology (ESMO) guidelines recommend adjuvant therapy for most patients with resected >T1N0 GCs, the recommendations vary regarding postsurgical treatment for patients with stage T1N+M0 or T2-3N0M0 disease. The JGCA guidelines do not recommend postsurgical chemotherapy for this patient population, while the ESMO support the adjuvant treatment. The NCCN has not offered a definitive recommendation on this issue. Through careful literature search, there is not yet randomized report on whether postsurgical chemotherapy benefits survival for patients with resected T1N+M0 or T2-3N0M0 GC. The first-line chemotherapy regimen for GC is fluorouracil plus platinum. Among fluorouracil, platinum is especially favored due to its less frequent and less severe adverse effects. This large multicenter phase III randomized controlled trial is led by Department of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui Medical University, and carried out in multiple Chinese centers, aiming to compare the safety and efficacy of capecitabine monotherapy versus no therapy in the adjuvant setting for patients with stage T1N+M0 or T2-3N0M0 GC undergoing R0 Resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Microscopically-confirmed gastric adenocarcinoma (cardia cancer/adenocarcinoma of the esophagogastric junction);
- •Cancer stage pT1N+M0 or pT2-3N0M0;
- •Radical R0 resection;
- •Retrieved lymph node number ≥15;
- •Without hepatic, peritoneal, or other distant metastasis;
- •Aged 18-70 years;
- •No other cancer-directed therapy except primary cancer resection;
- •Good tissue and organ function: white blood cell count ≥4000/mm3; neutrophil count ≥1500/mm3; platelet count ≥100000/mm3; total bilirubin ≤25.7 μmol/L or within 1.5 times the upper threshold; aspartate transaminase (AST) and alanine transaminase (ALT) within 2.5 times the upper threshold; creatinine within 1.25 times the upper threshold; creatinine clearance rate >60 mL/min;
- •No serious cardiovascular or cerebrovascular disease;
- •No concomitant or previous malignancies;
- •Enrolled within 6 weeks after resection;
- •Eastern Cooperative Oncology Group (ECOG) score ≤2;
- •Clavien-Dindo morbidity score 0-2;
- •Patient informed consent.
排除标准
- •The need to take phenytoin or coumarin anti-coagulates;
- •Allergic to capecitabine or fluorouracil;
- •Known DPD activity deficiency (DPYD gene mutation);
- •Pregnant or breeding women;
- •All others contradictory to the items listed in the Inclusion Criteria.
研究组 & 干预措施
Capecitabine monotherapy group
干预措施: Capecitabine monotherapy (Drug)
结局指标
主要结局
Disease-free/Relapse-free survival
时间窗: 5 years
The time interval from randomization to local recurrence/distant metastasis, death, or end of follow-up whichever occurs first.
次要结局
- Overall survival(5 years)
- Incidence of Treatment-Emergent Adverse Events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events(2 years)
- Health-related quality of life as assessed by European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30(5 years)
研究者
A-Man Xu
Professor, Chief Surgeon, Department Head
The First Affiliated Hospital of Anhui Medical University